February 13, 2023Open Access

Disentangling the Cost of Orphan Drugs Marketed in the United States

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

< 0.001). Higher market entry treatment cost for newly approved drugs were associated with biologics, orphan status, US sponsor companies, chronic use, therapeutic intent, and indications for oncology or genetic disorders.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Althobaiti et al. (Mon,) studied this question.

synapsesocial.com/papers/69ff48cef9e1acab462d5d44 https://doi.org/https://doi.org/10.3390/healthcare11040558

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures2018 · 62 citations
2What Is the Price Benchmark to Replace Average Wholesale Price (AWP)?2010 · 42 citations
3Estimating the clinical cost of drug development for orphan versus non-orphan drugs2019 · 125 citations
4Incentives for orphan drug research and development in the United States2008 · 138 citations
5The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities2014 · 75 citations

Me gusta

Guardar

Ver artículo completo